(Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating ...

LFT slightly high. There is no pain. No yellowing of the eyes. No weakness. So it is easy to brush it aside. But the liver rarely shouts in the beginning. It whispers.Liver Function Tests, or LFTs, ...